A portion of this work was presented at the 45th Annual Conference on Cardiovascular Disease Epidemiology and Prevention on May 2, 2005. NEPTUNE II was supported by funding from AstraZeneca Pharmaceuticals.
Ethnic Differences in Achievement of Cholesterol Treatment Goals
Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II
Article first published online: 12 APR 2006
Journal of General Internal Medicine
Volume 21, Issue 4, pages 320–326, April 2006
How to Cite
Clark, L. T., Maki, K. C., Galant, R., Maron, D. J., Pearson, T. A. and Davidson, M. H. (2006), Ethnic Differences in Achievement of Cholesterol Treatment Goals. Journal of General Internal Medicine, 21: 320–326. doi: 10.1111/j.1525-1497.2006.00349.x
- Issue published online: 3 MAY 2006
- Article first published online: 12 APR 2006
- Manuscript received May 20, 2005Initial editorial decision August 29, 2005Final acceptance November 7, 2005
- National Cholesterol Education Program guidelines;
- lipid treatment
BACKGROUND: African Americans (AA) have the highest coronary heart disease mortality rate of any ethnic group in the United States. Data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey were used to assess ethnic differences in low-density lipoprotein cholesterol (LDL-C) goal achievement.
METHODS: NEPTUNE II surveyed patients with treated dyslipidemia to assess achievement of treatment goals established by the Adult Treatment Panel III of the National Cholesterol Education Program. United States physicians working in primary care or relevant subspecialties enrolled 10 to 20 consecutive patients (May to September 2003), and patient data were recorded in Personal Digital Assistants and uploaded to a central database via the internet.
RESULTS: Among 4,885 patients receiving treatment for dyslipidemia, 79.7% were non-Hispanic white (NHW) and 8.4% were AA. Non-Hispanic white and AA patients had significantly different frequencies of treatment success, with 69.0% and 53.7%, respectively, having achieved their LDL-C goal (P<.001). African-American patients were more likely to be in the highest risk category, and less likely to be using lipid drug therapy, taking high-efficacy statins, and receiving care from a subspecialist, but the difference in goal achievement remained significant (P<.001) after adjustment for these and other predictors of treatment success.
CONCLUSIONS: The frequency of treatment success in dyslipidemia management was significantly lower in AA than NHW patients. Additional research is needed to elucidate reasons for this disparity and to evaluate strategies for improving goal achievement among AA patients receiving therapy for dyslipidemia.